6 257

Cited 204 times in

Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.

Authors
Hahm, KB; Cho, K; Lee, C; Im, YH; Chang, J; Choi, SG; Sorensen, PH; Thiele, CJ; Kim, SJ
Citation
Nature genetics, 23(2):222-227, 1999
Journal Title
Nature genetics
ISSN
1061-40361546-1718
Abstract
Chromosomal translocations resulting in the expression of chimaeric transcription factors are frequently observed in tumour cells, and have been suggested to be a common mechanism in human carcinogenesis. Ewing sarcoma and related peripheral primitive neuroectodermal tumours share recurrent translocations that fuse the gene EWSR1 (formerly EWS) from 22q-12 to FLI1 and genes encoding other ETS transcription factors (which bind DNA through the conserved ETS domain). It has been shown that transduction of the gene EWSR1-FLI1 (encoding EWS-FLI1 protein) can transform NIH3T3 cells, and that mutants containing a deletion in either the EWS domain or the DNA-binding domain in FLI1 lose this ability. This indicates that the EWS-FLI1 fusion protein may act as an aberrant transcription factor, but the exact mechanism of oncogenesis remains unknown. Because ETS transcription factors regulate expression of TGFBR2 (encoding the TGF-beta type II receptor, TGF-beta RII; Refs 9,14), a putative tumour suppressor gene, we hypothesized that TGFBR2 may be a target of the EWS-FLI1 fusion protein. We show here that Ewing sarcoma [corrected] (ES) cell lines with the EWSR1-FLI1 fusion have reduced TGF-beta sensitivity, and that fusion-positive ES cells and primary tumours both express low or undetectable levels of TGFBR2 mRNA and protein product. Co-transfection of FLI1 and the TGFBR2 promoter induces promoter activity, whereas EWSR1-FLI1 leads to suppression of TGFBR2 promoter activity and FLI1-induced promoter activity. Introduction of EWSR1-FLI1 into cells lacking the EWSR1-FLI1 fusion suppresses TGF-beta RII expression, whereas antisense to EWSR1-FLI1 in ES cell lines positive for this gene fusion restores TGF-beta RII expression. Furthermore, introduction of normal TGF-beta RII into ES cell lines restores TGF-beta sensitivity and blocks tumorigenicity. Our results implicate TGF-beta RII as a direct target of EWS-FLI1.
MeSH terms
AnimalsCell LineDNA-Binding Proteins/geneticsGene Expression Regulation/drug effectsHumansImmunohistochemistryLuciferases/geneticsLuciferases/metabolismMiceMice, NudeNeuroblastoma/geneticsNeuroblastoma/metabolismNeuroblastoma/pathologyOncogene Proteins, Fusion/geneticsOncogene Proteins, Fusion/physiology*Promoter Regions, Genetic/geneticsProtein-Serine-Threonine KinasesProto-Oncogene Protein c-fli-1Proto-Oncogene Proteins*RNA, Messenger/geneticsRNA, Messenger/metabolismReceptors, Transforming Growth Factor beta/genetics*Recombinant Fusion Proteins/geneticsRecombinant Fusion Proteins/metabolismSarcoma, Ewing's/geneticsSarcoma, Ewing's/metabolismSarcoma, Ewing's/pathologySequence DeletionTrans-Activators/geneticsTranscription Factors/geneticsTranscription Factors/physiology*TransfectionTransforming Growth Factor beta/pharmacologyTumor Cells, Cultured/drug effectsTumor Cells, Cultured/metabolism
DOI
10.1038/13854
PMID
10508522
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
AJOU Authors
함, 기백
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse